Here are four key notes:
1. The safety and effectiveness of Viberzi for treatment of IBS-D was established in two double-blind, placebo-controlled clinical trials which included 2,425 patients.
2. While the safety and effectiveness of Xifaxan for treatment of IBS-D was established in three double-blind, placebo-controlled trials.
3. Viberzi is manufactured by Patheon Pharmaceuticals and is distributed by Forest Pharmaceuticals. Xifaxan is marketed by Salix Pharmaceuticals.
4. The most common side effects in patients treated with Viberzi were constipation, nausea and abdominal pain. And common side effects in patients treated with Xifaxan for IBS-D included nausea and an increase in alanine aminotransferase, a liver enzyme measured in blood.
More articles on GI/endoscopy:
Lovell Federal Health Care Center opens new GI center
5 most-read GI/endoscopy stories – May 25 to May 29
Banner MD Anderson Cancer Center names Dr. Ivana Dzeletovic chief of endoscopy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.